Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))
Launched by ABBVIE (PRIOR SPONSOR, ABBOTT) · Jul 14, 2010
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This survey was conducted to assess the risk and benefit of continuing or discontinuing biological therapy with adalimumab (Humira) during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-859).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The participants were patients who continued treatment with adalimumab until the end of the treatment period in the NCT00870467(M06-859) study and provided informed consent to participate in the present follow-up survey.
- Exclusion Criteria:
- • Participants who used biological agents other than adalimumab after the period of treatment in the NCT00870467(M06-859) study were excluded from the present follow-up study.
About Abbvie (Prior Sponsor, Abbott)
AbbVie is a global biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories, focusing on the discovery, development, and commercialization of advanced therapies for complex diseases. With a commitment to innovation and patient-centric solutions, AbbVie leverages cutting-edge research and a robust pipeline to address unmet medical needs across various therapeutic areas, including immunology, oncology, and neuroscience. The company's dedication to advancing healthcare is underscored by its collaborative approach, engaging with healthcare professionals, patients, and stakeholders to deliver groundbreaking treatments that improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Anjo, , Japan
Aomori, , Japan
Chiba, , Japan
Chiba, , Japan
Chiba, , Japan
Fukuoka, , Japan
Gifu, , Japan
Hamamatsu, , Japan
Hiroshima, , Japan
Hyogo, , Japan
Hyogo, , Japan
Ibaraki, , Japan
Kagoshima, , Japan
Kagoshima, , Japan
Kawagoe, , Japan
Kawagoe, , Japan
Kawasaki, , Japan
Kirishima, , Japan
Kitakyushu, , Japan
Kumamoto, , Japan
Kyoto, , Japan
Maebashi, , Japan
Matsumoto, , Japan
Matsuyama, , Japan
Miyazaki, , Japan
Morioka, , Japan
Nagano, , Japan
Nagaoka, , Japan
Nagasaki, , Japan
Nagoya, , Japan
Nagoya, , Japan
Nara, , Japan
Niigata, , Japan
Oita, , Japan
Okayama, , Japan
Okayama, , Japan
Osaka, , Japan
Osaka, , Japan
Rifu, , Japan
Sagamihara, Kanagawa, , Japan
Saitama, , Japan
Saitama, , Japan
Sapporo, , Japan
Sapporo, , Japan
Sapporo, , Japan
Sapporo, , Japan
Sasebo, , Japan
Setouchi, , Japan
Shimotsuke, , Japan
Shizuoka, , Japan
Shizuoka, , Japan
Takamatsu, , Japan
Takasaki, , Japan
Tenri, , Japan
Tokorozawa, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tomigusuku, , Japan
Toyama, , Japan
Toyama, , Japan
Toyoake, , Japan
Toyohashi, , Japan
Tsu, , Japan
Yokohama, , Japan
Yokohama, , Japan
Yokohama, , Japan
Yokohama, , Japan
Yotsukaido, , Japan
Patients applied
Trial Officials
Aki Kuroki
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials